Purple Biotech (PPBT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PPBT Purple Biotech

Watchlist

2.940
-0.120-3.92%

Close Feb 25 16:00 ET

2.940
0.0000.00%

Post 20:01 ET

7.59MMarket Cap-0.39P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Purple Biotech Advances NT219 Into a Phase 2 Study In Head And Neck Cancer
BenzingaFeb 18 07:02 ET
Purple Biotech Advances NT219 Into Phase 2 Head and Neck Cancer Trial
GlobeNewswireFeb 18 07:00 ET
Purple Biotech Partners With Mount Sinai to Advance Cancer Immunotherapy
TipRanksFeb 3 07:28 ET
Purple Biotech Announces Research Collaboration With Icahn School of Medicine
TipRanksFeb 3 07:10 ET
Express News | Purple Biotech Announces Research Collaboration With the Icahn School of Medicine at Mount Sinai for Captn-3 Tri-Specific Antibody Platform
ReutersFeb 3 07:00 ET
Purple Biotech Expands ATM Offering by $1.33 Million
TipRanksJan 6 17:37 ET

Comments

Teddy123

Feb 18 06:25

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

$Purple Biotech (PPBT.US)$
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity

Jaguar8

Feb 18 06:01

NEWS

$Purple Biotech (PPBT.US)$
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...

103404493

Jan 22 06:24

$Edible Garden (EDBL.US)$

Share Your Profit/Loss

Jaguar8

Dec 5, 2024 06:13

NEWS

$Purple Biotech (PPBT.US)$
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...